** Shares of IDT Australia RIC rise 8.9% to A$0.098; marks biggest intraday percentage gain since January 28
** The pharma manufacturer secures manufacturing contract with Nacuity Pharmaceuticals Pty for NPI-001, an investigational treatment for retinitis pigmentosa
** Five-year contract with initial A$3.2 million ($1.91 million) work expected to complete by FY2026, adds co
** Stock down 18.2% this year, as of last close
($1 = 1.6753 Australian dollars)
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。